Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Dose-finding, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile of NOV140201 (JPI-547), a Dual Inhibitor of PARP/TNK in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

An Open-label, Dose-finding, Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile of NOV140201 (JPI-547), a Dual Inhibitor of PARP/TNK in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nesuparib (Primary)
  • Indications Advanced breast cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Onconic Therapeutics

    • Most Recent Events

    • 24 Mar 2023 Results of pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation (n=22) to assess the optimal dosing regimen of JPI-547 in patients with advanced solid tumor, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 01 Jun 2022 Status changed from recruiting to completed.
    • 08 Jun 2021 Interim results (Data cut off 31 Dec 2020) presented at the 57th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top